Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
14.99
+0.07 (+0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acadia Pharmaceutica
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Recap: ACADIA Pharmaceuticals Q4 Earnings
February 28, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer's Psychosis
February 16, 2022
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated...
Via
Benzinga
Expert Ratings For ACADIA Pharmaceuticals
February 09, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
February 16, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 14, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
February 11, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
February 09, 2022
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment...
Via
Benzinga
Bear Market Bets In Biotech
February 07, 2022
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
January 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders
January 10, 2022
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and Stoke Therapeutics Inc (NASDAQ: STOK) will team up on the treatments in rare genetic neurodevelopmental diseases of...
Via
Benzinga
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
January 10, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
January 05, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:
Via
Benzinga
What 17 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
January 05, 2022
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:
Via
Benzinga
$1000 Invested In This Stock 10 Years Ago, Would Be Worth This Much
December 28, 2021
ACADIA Pharmaceuticals (NASDAQ:ACAD) has outperformed the market over the past 10 years by 22.05% on an annualized basis. Buying $1,000 In ACAD: 10 years ago, an investor could...
Via
Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
December 27, 2021
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
December 23, 2021
Gainers Tempest Therapeutics (NASDAQ:TPST...
Via
Benzinga
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
December 22, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
55 Biggest Movers From Yesterday
December 22, 2021
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8...
Via
Benzinga
What Analysts Have To Say On Acadia's Narrower Nuplazid Label Expansion Bid
December 21, 2021
RBC Capital
Via
Benzinga
Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis
December 21, 2021
After suffering rejection from the FDA in April, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is making another bid to expand the scope of its Parkinson's disease...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 21, 2021
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4...
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
December 21, 2021
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining...
Via
Benzinga
Why This Acadia Pharmaceuticals Move Has Analysts Split — And Shares Down 20%
December 21, 2021
After a rejection in April, Acadia is planning to ask for approval in Alzheimer's patients.
Via
Investor's Business Daily
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 20, 2021
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD
Via
Benzinga
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
December 20, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Top Biotech Stocks: Trading Opportunities For Next Week
December 19, 2021
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns.
Via
Talk Markets
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
December 14, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.